Nektar Therapeutics | NKTR - 营业费用



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 15.95B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


营业费用 更改 日
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
ALKERMES USD 1.75B 1.43B 2026-03
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
Amgen USD 4.78B 1.12B 2026-03
Baxter International USD 6.04B 2.85B 2026-03
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Biogen USD 1.96B 69.6M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Cara Therapeutics USD 5.94M 983K 2025-09
Cipla INR 60.98B 1.06B 2025-12
Dr.Reddys Laboratories INR 73.6B 1.79B 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Merck USD 18.17B 8.01B 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Takeda JPY 1.02T 400.98B 2025-12
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Xencor USD 81.86M 13.35M 2025-12